Lubricant eye drops receive CE Mark

NovaTears has received the CE Mark of approval for the treatment of dry eyes, according to the latest press release from Novaliq.

The firm developed the drug for use as a topical eye lubricant based on the proprietary technology EyeSoi. NovaTears is a multi-dose, non-aqueous, non-blurring and preservative-free topical eye drop for lubrication of the ocular surface.

Novaliq received a fifth round of financing, with help from Dievini Hopp Bio Tech Holding, raising a total of €13.9 million in April 2013. This funded the ongoing development of its ophthalmic portfolio, including CyclASol Rx as well as additional OTC products.

Bernhard Huenther, CEO of Novaliq, commented, “We are pleased to receive CE mark approval for our first ophthalmic product designed to improve the quality of life for the dry eye OTC patient. It offers a significant new product choice for the European consumer; innovative Novaliq technology that contains no preservatives, yet is available in conventional, multi-dose bottles. The absence of irritating surfactants and preservatives provides dry eye patients improved tolerability and convenience.”

Mathias Hothum, Managing Director of Dievini Hopp Bio Tech Holding, stated, “We congratulate Novaliq on obtaining the CE mark for NovaTears OTC and look forward to future product additions to the SFA portfolio. We are pleased to help Novaliq further its pioneering ocular drug delivery technology and strong management team.”